SeaStar Medical shares fell 44.7% after earnings, with the clearest disappointment being a delay in the NEUTRALIZE-AKI trial: enrollment is now expected to finish by mid-2027. QUELIMMUNE sales grew sharply, but that progress was overshadowed by the slower timeline for the pivotal adult AKI study.
SeaStar Medical shares dropped 13.2% as investors reacted negatively to cautious guidance and ongoing clinical trial enrollment delays that cloud near-term revenue growth visibility.
SeaStar Medical’s stock dropped 13.2% after the quarter, driven primarily by cautious commentary on the pace of enrollment in the NEUTRALIZE-AKI pivotal trial and the still small commercial scale of QUELIMMUNE revenue, which constrains near-term growth visibility.